• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GeNO doubles executive management team

GeNO doubles executive management team

January 20, 2012
CenterWatch Staff

GeNO, a privately held technology company, has hired four new senior executives and promoted two others, more than doubling its executive management team.

New hires to the executive management team are:

Kurt Dasse, Ph.D., former president and founder of recently-sold Levitronix, was named executive vice president of GeNO. Dasse has spent nearly three decades conducting research in cardiovascular disorders and developing and commercializing medical devices. He has written more than 100 journal articles and multiple book chapters, and holds several patents.

Jack Whiting, former vice president, general counsel of Levitronix, will serve as vice president of operations. Whiting will be responsible for finance, legal, human resources and risk management functions, as well as supply chain management.

Daniel O'Donnell, former vice president, business development at L-3 CyTerra was appointed general manager. O'Donnell will be responsible for managing daily operations and new R&D business pursuits.

Ed Bromberg, Ph.D., previously at L-3 CyTerra and Thermo, will serve as R&D manager. Bromberg brings more than 34 years of experience in the development of scientific instrumentation from concept to release to production.

Promoted members of the executive management team are:

Robert Roscigno, Ph.D., was promoted to executive vice president. Roscigno has a unique combination of clinical development, sales, marketing and business expertise in the pharmaceutical industry, with over 16 years of drug development experience.

Lucas Gamero, Ph.D., was promoted to vice president of R&D. Gamero has 15 years of experience in research and new product development in the medical device and pharmaceutical industry.

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing